Golden has been acquired by ComplyAdvantage.Read about it here ⟶

Dimension Therapeutics

Dimension Therapeutics is a biotechnology company that uses gene therapy to treat liver diseases.

Overview Structured Data Issues Contributors Activity

All edits

Edits on 16 Feb, 2024

"NL fact extraction"

Golden Au

edited on 16 Feb, 2024

Edits made to:

Infobox (+1/-1 properties)

Infobox

Number of Employees (Ranges)

51 – 200

Number of Employees (Ranges)

10,001+0

Edits on 24 May, 2023

"Clean up website values by canonicalizing and removing duplicates"

Golden AI

edited on 24 May, 2023

Edits made to:

Infobox (-1 properties)

Infobox

Official Website

http://www.dimensiontx.com/

Edits on 6 May, 2023

"Covert AngelList URL to Wellfound ID"

Golden AI

edited on 6 May, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Wellfound ID

dimension-therapeutics

Edits on 16 Mar, 2023

"prospector:2473:2560445"

Katrina-Kay Pettitt

edited on 16 Mar, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Industry

Biotechnology

"prospector:2472:2545171"

Katrina-Kay Pettitt

edited on 16 Mar, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Industry

Biology

Edits on 22 Feb, 2023

"prospector:2317:2474292"

Katrina-Kay Pettitt

edited on 22 Feb, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Industry

Technology

Edits on 22 Jul, 2022

"clean up phone number value"

Golden AI

edited on 22 Jul, 2022

Edits made to:

Infobox (+1/-1 properties)

Infobox

Phone number

617-401-00110

Phone number

+161740100110

Edits on 3 Jul, 2022

Patrick Pum

edited on 3 Jul, 2022

Edits made to:

Infobox (+1 properties)

Infobox

CIK number

1,592,2880

Full address

840 MEMORIAL DRIVE 4TH FLOOR CAMBRIDGE MA 021390

IRS number

463,942,1590

Phone number

617-401-00110

Place of incorporation

Delaware

SIC code

2,8360

Edits on 17 May, 2022

"prospector:1525:760507"

Katrina-Kay Pettitt

edited on 17 May, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Is a

Organization

Edits on 7 May, 2022

Tim D

edited on 7 May, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Crunchbase

https://www.crunchbase.com/organization/dimension-therapeutics

Edits on 7 Jun, 2021

Neelam Jhaveri

approved a suggestion from Golden's AI on 7 Jun, 2021

Edits made to:

Article (+11/-11 characters)

Article

Dimension Therapeutics is an American biotech company founded by Ben AuspitzBen Auspitz and Allan M. Fox in 2013. The company conducts clinical trials and tests with a focus on finding cures to rare diseases. It uses its gene therapy to develop treatments and programs for haemophilia and adeno-associated virus therapeutics. It has been acquired by Ultragenyx Pharmaceutical.

Edits on 4 Jun, 2021

"Infobox creation from: Wikidata data enrichment"

Golden AI

approved a suggestion from Golden's AI on 4 Jun, 2021

Edits made to:

Infobox (+2 properties)

Infobox

Country

United States

Website

http://www.dimensiontx.com/

"Approved suggestion #1082931"

Henry Ogolla

approved a suggestion from Golden's AI on 4 Jun, 2021

Edits made to:

Infobox (+1 properties)

Infobox

Wikidata ID

Q30268909

Edits on 11 May, 2021

"Funding autocalculation"

Golden AI

edited on 11 May, 2021

Edits made to:

Infobox (+1 properties)

Infobox

Latest funding type

Private equity

Edits on 28 Mar, 2021

"Found on funding round"

Golden AI

edited on 28 Mar, 2021

Edits made to:

Infobox (+6 properties)

Infobox

Investors

Eight Roads Ventures

OrbiMed

New Leaf Venture Partners

RA Capital Management

Partner Fund Management

Jennison Associates

Edits on 3 Mar, 2021

"Funding autocalculation"

Golden AI

edited on 3 Mar, 2021

Edits made to:

Infobox (+1/-1 properties)

Infobox

Total funding amount (USD)

109,999,986

Total funding amount (USD)

169,499,986

Edits on 28 Feb, 2021

Henry Ogolla

approved a suggestion from Golden's AI on 28 Feb, 2021

Edits made to:

Article (+25/-25 characters)

Article

Dimension Therapeutics is an American biotech company founded by Ben Auspitz and Allan M. Fox in 2013. The company conducts clinical trials and tests with a focus on finding cures to rare diseases. It uses its gene therapy to develop treatments and programs for haemophilia and adeno-associated virus therapeutics. It has been acquired by Ultragenyx PharmaceuticalUltragenyx Pharmaceutical.